Antibacterial activity of ciprofloxacin and trimethoprim, alone and in combination, against Vibrio cholerae O1 biotype E1 Tor serotype Ogawa isolates

• Autorzy: Mandal S , Pal N.K. , Chowdhury I.H. , Debmandal M.
• Języki publikacji: EN

Abstrakty

EN

In this communication, the ciprofloxacin-trimethoprim (Cp-Tm) combination showed synergistic (Fractional Inhibitory Concentration, FIC index 0.399) and additive (FIC index 0.665-0.83) effects against Vibrio cholerae O1 biotype El Tor serotype Ogawa isolates having Cp MICs 10 μg/ml and Cp 0.66 μg/ml, respectively, following agar dilution checkerboard method. The time-kill study results demonstrated synergy between Cp and Tm against both groups of isolates providing 2.04 log₁₀ (for strain with Cp MIC 0.66 μg/ml) and 3.12 log₁₀ (for strain with Cp MIC 10 μg/ml) decreases in CFU/ml between the combination and its most active compound. Thus, the findings of the present study suggest an introduction of Cp-Tm combination treatment regimen against drug resistant cholera and this in turn will help in combating the drug resistance of V. cholerae O1 biotype El Tor serotype Ogawa.

Słowa kluczowe

EN

cholera; Vibrio cholerae; antibiotic therapy; trimethoprim; human disease; drug resistance; ciprofloxacin; antibacterial activity; fractional inhibitory concentration index

• Wydawca: -
• Czasopismo: Polish Journal of Microbiology
• Rocznik: 2009
• Tom: 58
• Numer: 1
• Opis fizyczny: p.57-60,fig.,ref.

Twórcy

autor

Mandal S

• Calcutta School of Tropical Medicine, C.R.Avenue, Kolkata-700 073, India

autor

Pal N.K.

autor

Chowdhury I.H.

autor

Debmandal M.

Bibliografia

• Bertolini, A., M. Castelli, S. Genedani and M. Garuti. 1980. Trimethoprim enhances the antimicrobial activity of nalidixic acid and oxolinic acid and delays the emergence of resistance. Experimentia. 36: 243-244.
• Bhattacharya M. K., D. Dutta, T. Ramamurthy, D. Sarkar, A. Singharoy and S. K. Bhattacharya. 2003. Azithromycin in the treatment of cholera in children. Acta. Pediatr. 92: 676-678.
• Craig W. A. and B. Vogelman. 1987. The Post antibiotic effect. Annals Internal Med. 106:900-902.
• Das S. and S. Gupta. 2005. Diversity of Vibrio cholerae strains isolated in Delhi, India, during 1992-2000. J. Health Popul. Nutr. 23: 44-51.
• Garg P., S. Chakraborty, I. Basu, S. Datta, K. Rajendran, T. Bhattacharya, S. Yamasaki, S. K. Bhattacharya, Y. Takeda, G. B. Nair and T. Ramamurthy. 2000. Expanding multiple antibiotic among clinical strains of Vibrio cholerae isolated from 1992-7 in resistance Calcutta, India. Epidemiol. Infect. 124: 393-399.
• Garg P., S. Sinha, R. Chakraborty, S.K. Bhattacharya, G.B. Nair and T. Ramamurthy. 2001. Emergence of fluroquinolone resistant strains of Vibrio cholerae O1 biotype El Tor among hospitalized patients with cholera in Calcutta, India. Antimicrob. Agents Chemother. 45: 1605-1606.
• Genedani S., M. Castelli, P. Foresta and A. Bertolini. 1983. Oxolinic acid-trimethoprim combination: Effects on DNA synthesis and on viability of Escherichia coli. Chemotherapy. 29: 24-27.
• Huovinen P., J.S. Wolfson and D.C. Hooper. 1992. Synergism of trimethoprim and ciprofloxacin against clinical bacterial isolates. Eur. J. Clin. Microbiol. Infect. Dis. 11: 255-257.
• Krogstad D.J. and R.C. Moellering. 1980. Combinations of antibiotics, mechanisms of interaction against bacteria, pp. 298-341. In: Lorian V. (ed). Antibiotics in Laboratory Medicine. The Williams and Wilkins Co., Baltimore.
• Leclercq R., E. Bingen, Q.H. Su, N. Lambert-Zechovski, P. Courvalin and Duval. 1991. Effects of combinations of β-lactams, daptomycin, gentamycin and glycopeptides against glycopeptide resistant Enterococci. Antimicrob. Agents Chemther. 35: 92-98.
• Mandal S., M.D. Mandal and N.K. Pal. 2003a. Combination effect of ciprofloxacin and gentamicin against clinical isolates of Salmonella enterica serovar Typhi with reduced susceptibility to ciprofloxacin. Jpn. J. Infect. Dis. 56: 156-157.
• Mandal S., M.D. Mandal and N.K. Pal. 2003b. In vitro efficacy of ciprofloxacin alone and in combination with amoxycillin against Salmonella typhi isolates. Indian J. Exp. Biol. 41: 360-362.
• Mandal S., M.D. Mandal and N.K. Pal. 2004a. Synergism of ciprofloxacin and trimethoprim against Salmonella enterica serovar Typhi isolates showing reduced susceptibility to ciprofloxacin. Chemotherapy. 50: 152-154.
• Mandal S., M.D. Mandal and N.K. Pal. 2004b. Evaluation of combination effect of ciprofloxacin and cefazolin against Salmonella enterica serovar Typhi isolates by in vitro methods. Calicut Med. J. 2, e2. URL: http://www.calicutmedicaljournal. org/2004/2/2/e2
• National Committee for Clinical Laboratory Standards: Methods for dilution antimicrobial susceptibility test for bacteria that grow aerobically; Approved Standards. 1997. NCCLS, Wayne, Pa. USA.
• Saha D., W.A. Khan, M.M. Karim, H.R. Chowdhury, M.A. Salam and M. L. Bennish. 2005. Single-dose ciprofloxacin versus 12-dose erythromycin for childhood cholera: a randomised controlled trial. Lancet. 366: 1054-1055.
• Samal B., S.K. Ghosh, S.K. Mohanty and K. Patnaik. 2001. Epidemic of Vibrio cholerae serogroup O139 in Berhampur, Orissa. Indian J. Med. Res. 114: 10-11.
• Sengupta P.G., S.K. Niyogi and S.K. Bhattacharya. 2000. An outbreak of El Tor cholera in Aizwal town of Mizoram. Indian J. Commun. Dis. 32: 207-211.
• Taneja N., M. Biswal, B. Tarai and M. Sharma. 2005. Emergence of Vibrio cholerae O1 Biotype El Tor serotype Inaba in north India. Jpn. J. Infect. Dis. 58: 238-240.
• Vogelman B. and W.A. Craig. 1986. Kinetics of antimicrobial activity. J. Paediatrics. 108: 835-840.
• Westh H., N. Fimodt, E. Crutschick and J. Bangsborg. 1992. Killing curve activity of ciprofloxacin is comparable to synergistic effect of b-lactam tombramycin combination against Haemophilus species endocarditis strains. APMIS. 100: 856-860.